On September 8, 2022 Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, reported that Oren Gilad Ph.D, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022 at 12:30 p.m. ET (Press release, Aprea, SEP 8, 2022, View Source [SID1234619241]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation will discuss Aprea’s discovery program and development pipeline in synthetic lethality and DDR, including:
ATRN-119, the Company’s Phase 1-ready small molecule ATR inhibitor
ATRN-W1051, the Company’s WEE1 inhibitor in preclinical development
Repli-Biom, the Company’s discovery platform to identify both new precision oncology targets and patient populations most likely to benefit from treatment
Eprenetapopt, the Company’s clinical-stage small molecule p53 reactivator
A copy of the presentation will be accessible from the "Events Calendar" in the News and Events section of the Aprea website.